AuthorisedHuman Pharmacology (Phase I)- First administration to humansInterventional

A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis

This early-stage medical study is testing a new medicine called LFD-200. It's designed for people in the UK who have rheumatoid arthritis that is moderate to severe, meaning it affects their daily life. Healthy volunteers are also taking part. The main aim is to find out if different doses (amounts) of LFD-200 are safe and well-tolerated. Researchers also want to understand how the medicine behaves once it's in the body. This is a very early study, the first time this medicine is being given to people, so it's a crucial step in its development.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- First administration to humans

Sponsor

Lifordi Immunotherapeutics Inc.

Enrolment target

Start

30 Jan 2026

Moderate to Severe Rheumatoid Arthritis

What is this study about?

This research is about a new medicine, currently known as LFD-200. It's being developed as a possible treatment for people living with moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a long-term condition that causes pain, swelling, and stiffness in the joints. For some people, standard treatments don't work as well as hoped, making new medicines very important.

The main purpose of this study is to test LFD-200 for the very first time in people. This type of study is known as a 'Phase 1' trial. Researchers want to carefully check how safe different amounts of the medicine are when given to healthy people and people with rheumatoid arthritis. They will also look at how the body handles the medicine, for example, how much of it gets absorbed and how quickly it leaves the body.

Learning about the safety and how the medicine works in the body is a vital first step. If the medicine proves to be safe and shows some promise, it could then move on to larger studies to see how effective it is in treating rheumatoid arthritis symptoms. This early research helps doctors decide if LFD-200 has the potential to become a useful treatment in the future.

Key takeaways

This is an early study of a new medicine (LFD-200) for rheumatoid arthritis.
The main goal is to check how safe different doses are.
Both healthy adults and adults with moderate to severe rheumatoid arthritis can take part.
Participation involves clinic visits and careful health monitoring.
You can stop taking part at any time without affecting your normal care.

Who may be eligible?

To join this study, you need to be an adult, aged 18 years or older. This study is open to both men and women.

Since this is an early study, researchers are looking for two main groups of people. One group will be healthy volunteers, meaning they don't have rheumatoid arthritis or other significant health problems. The other group will be people diagnosed with moderate to severe rheumatoid arthritis.

There will be other specific health requirements for both groups, which a doctor and study team will discuss with you. These details help make sure the study is safe for everyone involved and that the results are clear. Your doctor will help you understand if you might be a good fit.

Quick self-check

Are you 18 years old or older?
Do you have moderate to severe rheumatoid arthritis, or are you a healthy adult?
Are you able to attend regular clinic visits?
Are you willing to follow study instructions carefully?

This is a guide only — the research team will confirm whether you can take part.

What does participation involve?

If you decide to take part, you would receive the study medicine, LFD-200. This is the first time this medicine is being given to people. The study involves several visits to the clinic, where you'll have regular health checks. These checks might include blood tests, physical examinations, and possibly scans. Doctors will closely monitor how you are feeling and how your body is reacting to the medicine.

You will be given a specific dose of the medicine, and the study team will track any effects it has, both good and bad. There will be follow-up appointments even after you stop taking the medicine, to make sure you are well. The total time you would be involved in the study will depend on the specific group you are in, and all these details will be explained to you before you agree to participate.

Potential risks and benefits

Taking part in any medical study has potential benefits and potential risks. A potential benefit of this study could be access to a new medicine not yet available to the public, which might help manage your rheumatoid arthritis if you're in that group. You will also receive careful medical monitoring. However, there's always a risk that the new medicine might cause side effects, some of which could be unexpected or serious. Since this is the first time the medicine is given to humans, it's not fully known what all the effects might be. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

—
Poland

Common questions

What is LFD-200?

LFD-200 is a new medicine being developed that might help people with rheumatoid arthritis. This study is an early step in finding out more about it.

Why are healthy people taking part?

Healthy volunteers help researchers understand how the medicine works in a healthy body before it's given to people who are unwell. This helps to check its safety.

Will I know if I'm getting the active medicine or a dummy pill?

In early studies like this, everyone usually receives the active medicine, but different doses might be given to different groups. The study team will explain exactly what to expect.

How long will I be involved in the study?

The exact length of your participation will be fully explained by the study team. It will involve several clinic visits and follow-up appointments.

Can I leave the study once I've started?

Yes, you can choose to leave the study at any point, for any reason, and it will not affect your regular medical care.